Anti-NASH agent 1 (compound 3d),a derivative of Elafibranor ,is a potent agonist of PPAR-α/δ,targeting to nonalcoholic steatohepatitis (NASH). Anti-NASH agent 1 (3-10 mg/kg; 4 weeks) improves perlipidemia,liver fat degeneration and liver inflammation in Methionine-choline deficiency (MCD) induced NASH mice model. Anti-NASH agent 1 shows low liver toxicity and potent liver protection effect.
References:
[1]. Xiang C, et al. Design, synthesis and anti-NASH effect evaluation of novel GFT505 derivatives in vitro and in vivo. Eur J Med Chem. 2023 Sep 5;257:115510.
















